Publications, Abstracts & Presentations

  1. RNA Disruption Assay (RDA) as a biomarker of pCR in NeoAdjuvant trastuzumab-treated HER2-positive breast cancer Toomey S, Eustace AJ, Pritzker, L.B.; Pritzker, K.P.H.; Fay J, O’Grady A, Cummins R, O’Connor D, Young, L, Kay E, O’Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT
    NCI J Natl Cancer Inst (2016) 108 (8) djw111, First published online July 4, 2016 , doi:10.1093/jnci/djw111
  2. RNA Disruption Assay (RDA) as a biomarker of pCR in NeoAdjuvant trastuzumab-treated HER2-positive breast cancer Trudeau, M. E.
    JNCI J Natl Cancer Inst (2016) 108 (8): djw105 First published online July 4, 2016, doi:10.1093/jnci/djw105
  3. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines
    Pritzker, K.P.H.; Pritzker,L. B.; Generali, D.; Bottini, A.; Cappelletti, M. R.; Guo, B.; Parissenti, A. M.; Trudeau, M.E.
    BMC Cancer (2016) 16:146. Published online, Febrary 24, 2016
    DOI 10.1186/s12885-016-2197-1
  4. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy
    Parissenti, A.M.; Guo, B.; Pritzker,L.B.; Pritzker, K. P. H.; Wang, X.; Zhu, M.; Shepherd, L.; Trudeau, M. A.
    Breast Cancer Research and Treatment DOI 10.1007/s10549-015-3498-9 Published online July 25,2015 August 2015, Volume153(Issue1) Page p.135To-144
  5. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy
    Pritzker, K.P.H.; Pritzker,L. B.; Generali, D.; Bottini, A.; Cappelletti, M. R.; Guo, B.; Parissenti, A. M.; Trudeau, M.E.
    JNCI Monographs 2015 2015 (51): 76-80
    doi: 10.1093/jncimonographs/lgv015
  6. Novel anti-hormonal agent, AT-001, impairs androgen-independent prostate tumor growth by suppressing the relaxin signaling pathway
    Anton Neschadim, Laura B. Pritzker, Kenneth P.H. Pritzker, Donald R. Branch, Alastair J.S. Summerlee, John Trachtenberg, Joshua D. Silvertown
    Endocrine- Related Cancer 2014 21;3 459 -471 ERC-14-0088.R1
  7. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy
    Chiara Foroni, Carla Strina, Manuela Milani, Mariarosa Cappelletti, Claudia Fumarola, Mara Bonelli, Ramona Bertoni, Giuseppina Ferrero, Elena Takano, Daniele Andrei*, Sergio Venturini, Giulia Brugnol, Pier Giorgio Petronini, Roberto Giardini, Laura Pritzker, Kenneth Pritzker ,Amadeo Parissenti, Alfredo Berruti, Stephen B Fox, Alberto Bottini, Daniele Generali
    Breast Cancer Research and Treatment 2014, 144 113-121
  8. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients
    Amadeo M. Parissenti, Judy-Anne W. Chapman, Harriette J. Kahn,
    Baoqing Guo, Lei Han, Patti O’Brien, Mark P. Clemons, Roberta Jong,
    Rebecca Dent, Barbara Fitzgerald, Kathleen I. Pritchard, Lois E. Shepherd,
    Maureen E. Trudeau
    Breast Cancer Research and Treatment 2010:119, 347-356

  1. Abstract P1-09-19: Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy
    A Samkari, W Chung, A Parissenti, L Pritzker, N Trabulsi, M Basik and J-F Boileau
    DOI: 10.1158/1538-7445.SABCS16-P1-09-19 Published February 2017
  2. High tumor RNA disruption is associated with increased survival in patients with locally advanced breast cancer
    Parissenti, A; Guo, B; Pritzker, L; Pritzker, K; Wang, X; Zhu, M; Trudeau, M
    Cancer Res December 15, 2013 73:24 Supplement P1-08-24;
  3. Docetaxel-induced alterations in cellular RNA in ovarian cancer cells
    Narendrula,R; Guo, B; Lanner, C;. Parissenti, A.
    FASEB Journal 2013; 27:lb149
  4. Increased Pathologic Complete Response Rate and Reduced Tumour RNA Levels Upon Treatment of Locally Advanced Breast Cancer with Neoadjuvant Concurrent Chemotherapy and Radiation
    Brackstone, M; Chambers, A; Guo, B; Vandenberg, T; Potvin, K; Perea, F;Parissenti, A.
    Cancer Research December 17, 2012 72:P1-14-13
  5. A Novel RNA test to guide Primary Systemic Breast Cancer Chemotherapy
    ME Trudeau, LB Pritzker, AM Parissenti, X Wang, M Zhu, B Guo, LE Shepherd, J-A W Chapman, KPH Pritzker
    Annals of Oncology, V23, Supplement 2, May 2012 p19
  6. Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients.
    AM Parissenti, AM; Chapman,JA; Kahn,HJ; Guo, B. Han, L.;O’Brien, P.; Clemons, M; Jong,R; Dent, R; Fitzgerald, B; Pritchard, K. Shepherd,L and Trudeau M
    Cancer Research February 19, 2009 69:6068

  1. Cost-effectiveness of RNA Diagnostic Assay versus standard diagnostic testing for response-guided management of neoadjuvant chemotherapy in women with early/locally-advanced breast cancer in the UK
    Nam, J.; Noubir,S.;; Nam, A.; Pritzker, K.P.H.
    Canadian Agency for Drugs and Technologies in Health(CADTH) Symposium,
    Ottawa, Ontario, April 11,2016
  2. RNA Disruption Assay, Better Response Biomarker for Breast Cancer
    Pritzker, K. P. H.
    Grand Rounds, Clinica Las Condes, University of Chile
    Santiago, Chile, March 16, 2016
  3. RDA as a predictive and prognostic tool early in treatment for cancer chemotherapy and targeted therapy response
    Pritzker, K.P. H.
    Giornate di Oncologia Molecolare “From Bench to Bedside
    Università degli Studi di Trieste
    Trieste, Italy, Februray 19, 2016
  4. Advancing cancer diagnostics: Key to advancing cancer therapeutics, reducing adverse side effects and saving costs
    Pritzker, K.P.H..
    OICR, MaRS, World Cancer Day Event, Breaking the Mold: Rethinking the Cancer System
    Toronto, Canada, February 4, 2016
  5. RNA Disruption Assay: Recent progress
    Pritzker, K.P.H.
    University of Newcastle, NSW, Australia, January 28, 2016
  6. Feasibility of Fine Needle Aspiration FNA biopsies at first cycle of neoadjuvant Chemotherapy.
    Boileau JF
    Locally Advanced Breast Cancer National Consensus, Cambridge Ontario May 03-04, 2015
  7. Rna Disruption Assay(RDA) can Facilitate Response Guided therapy for Breast Cancer
    Pritzker,K.P.H.
    Baylor College of Medicine, Houston Texas USA, May 1, 2015
  8. New practices in monitoring the efficiacy of breast cancer chemotherapy
    Pritzker, KPH
    Key Experts Workshop, Swiss Creative Centre, Canton de Neuchâtel, Neuchâtel, Switzerland March 24, 2015
  9. Kostenvergleich des RNA Disruption Assay (RDA™) im Vergleich zur Sonographie für die response-gesteuerte neoadjuvante Behandlung von Brustkrebs in Deutschland
    Rautenberg TA ; Rosery H
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen
    Gesellschaften für Hämatologie und Medizinische Onkologie(DGHO) 2014
    October 13, 2014
  10. Feasibility of Fine Needle Aspiration FNA biopsies at first cycle of neoadjuvant Chemotherapy.
    Boileau JF
    Locally Advanced Breast Cancer National Consensus, Cambridge Ontario May 03-04, 2015
  11. Tumour RNA Disruption: An Effective Biomarker for Monitoring Clinical Response and Disease-free Survival After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
    Parissenti, A., Guo,B; Pritzker, L; Pritzker, K.; Wang, S.; Zhu, M.; Narendrula,R.; Lanner, C.; Shepherd, L.; Trudeau, M.
    RNA Society, Quebec City Canada, June 3, 2014
  12. RNA Disruption and the RNA Disruption Assay(RDA)
    Pritzker, KPH
    In Symposium: RDA, Key Tool to Guide Cancer Chemotherapy, London, UK, May 22, 2014
  13. Tumour RNA Disruption Is Superior to Pathologic Complete Response in Predicting Disease-Free Survival After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
    Parissenti, A.
    Locally Advanced Breast Cancer, Consensus Conference, Cambridge Ontario, Canada, May 5, 2014
  14. RDA: Key to Response Guided Therapy
    Pritzker, KPH
    University of Newcastle, Newcastle, Australia, January 31, 2014
    7. High Tumour RNA disruption is associated with increased Survival in patients with locally advanced Breast Cancer
    A.M. Parissenti , B. Guo, L. Pritzker, K. Pritzker, X. Wang, M. Zhu, M.E. Trudeau
    San Antonio Breast Cancer Symposium, San Antonio Texas, USA, December 11 2013
  15. RNA Disruption: Key to Response Guided therapy
    Pritzker, KPH
    Ariake hospital, Tokyo , Japan, October 10,2013
  16. RNA Disruption Assessment By Anti-Cancer agents
    R. Narendrula, C. Lanner, B. Guo, S. Santi, L. Pritzker, K. Pritzker, A. Cox, and A. M. Parissenti
    5th International Symposium on Primary Systemic Therapy in the Management of Operable Primary Breast Cancer, Cremona Italy, October 7, 2013
  17. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy
    Kenneth Pritzker, Laura Pritzker, MariaRosa Cappelleti Daniele Generali, Alberto Bottini,
    Maria Rosa Cappelletti, Baoqing Guo, Amadeo Parissenti, Maureen Trudeau
    5th International Symposium on Primary Systemic Therapy in the Management of Operable Primary Breast Cancer, Cremona Italy, October 7, 2013
  18. Determining Triple Negative Breast Cancer Patients not Responding to Chemotherapy; A Novel RNA Test
    KPH Pritzker, ME Trudeau, LB Pritzker, , X Wang, M Zhu, B Guo, LE Shepherd, J-A W Chapman , AM Parissenti
    Triple Negative Breast Cancer Conference 2013, London England, June 27, 2013
  19. The Rna Disruption assay(RDA) has the potential to be a cost-effective healthcare technology in detecting nonresponse to breast cancer chemotherapy
    Trudeau M , Chin W , Ariano G
    Applied Research in Cancer Control Meeting (ARCC), Vancouver, B.C. Canada, May 27, 2013
  20. Docetaxel-induced quantitative and qualitative changes in cellular RNA in human A2780 ovarian cancer cells
    Narendrula, R; Guo, B; Lannér, C; Parissenti, A.
    FASEB, April 2013
  21. Increased Pathologic Complete Response Rate and Reduced Tumour RNA Levels Upon Treatment of Locally Advanced Breast Cancer with Neoadjuvant Concurrent Chemotherapy and Radiation
    M. Brackstone A.F. Chambers, B.Guo , T. Vanderberg, K. Potvin, F. Perera A.M.Parissenti
    San Antonio Breast Cancer Symposium, San Antonio Texas, USA December 5, 2012 (P1-14-13)
  22. Association of RNA Integrity with Chemotherapy Drug Treatment in Cancer Cells
    B Guo, K Reed, AM Parissenti
    Riboclub, Mont Orford, Quebec, Canada, September 25, 2012
  23. A Novel RNA test to guide Primary Systemic Breast Cancer Chemotherapy
    ME Trudeau, LB Pritzker, AM Parissenti, X Wang, M Zhu, B Guo, LE Shepherd, J-A W Chapman , KPH Pritzker
    IMPAKT Breast Cancer Conference, Brussels Belgium, May 5, 2012
    Riboclub, Mont Orford, Quebec, Canada, September 25, 2012
  24. Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients.
    AM Parissenti, AM; Chapman,JA; Kahn,HJ; Guo, B. Han, L.;O’Brien, P.; Clemons, M; Jong, R; Dent, R; Fitzgerald, B; Pritchard, K. Shepherd,L and Trudeau M
    San Antonio Breast Cancer Symposium 2008 San Antonio Texas USA December 10,2008
  25. Gesundheitsökonomische Analyse de Verwen bei der Response-gesteurerten neoadjuvanten Brustkrebs therapie in Deutchland
    Rautenberg TA ; Rosery H
    Seinologie, Berlin, June 26, 2014

The Chemo Response Company